Gilead Sciences Inc.'s shares jumped 4.46% in the past week, while the increment turned out to be 2.45% over the past 4 weeks.

Over the past week, the company witnessed an overwhelming performance in the share market with increase in the S&P 500 by 3.26%. In the past quarter, the company's shares rose 12.64%.

The elevation in the share value of past 52 weeks turns out to be 27.86% for Gilead Sciences. As on June 24 this year, Gilead's shares recorded one year high of $123.37. It saw a one year low at $85.95 on December 23, last year.

Now, a number of market analysts are sending in suggestions for the company for further course of action. In fact, as many as five analysts have rated Gilead as a potential unit for investment.

Only one analyst stated that the company has underperformed while 14 more gave a thumbs-up to its performance.

According to the analysts, Gilead is expected to achieve a long-term growth estimate of $13.52. This estimate will include sales as well as the earnings made over the next three to five years.

Gilead Sciences is a research-oriented biopharmaceutical company. It specializes in research and development of new medicines and their commercialization further.

Gilead's specializes in pharma pertaining to diseases like human immunodeficiency virus (HIV)/AIDS, liver diseases (hepatitis B and C), heart and respiratory ailments.

It is majorly active in North America, Europe and Asia Pacific.